Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

NCT07313462 | Recruiting

• 1 other identifier: 9535
• Study Type: observational
• Target: 830
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Conditions

Multiple Sclerosis (MS)

Keywords

Multiple Sclerosis (MS); Escalation Therapy; Induction Therapy

Outcome Measures

Primary Outcomes (1)

• Time to First Clinical Inflammatory Relapse

  Compare the time to first clinical inflammatory relapse between two groups of patients who developed relapsing-remitting MS (RRMS) after age 50: * Group 1 = therapeutic escalation strategy: starting with a moderately effective treatment (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon) * Group 2 = induction strategy: starting with a highly effective treatment (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

  Up to 12 months

Eligibility Criteria

• Age: 50 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with RRMS onset after age 50

You may qualify if:

• Patients with RRMS onset after age 50
• Patients who started their first disease-modifying therapy within 2 years of the first symptoms
• Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
• Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

You may not qualify if:

• \- Patients with early progressive MS

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Centre d'Investigation Clinique - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Nicolas Collongues, MD

CONTACT

33 3.88.12.87.33; nicolas.collongues@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 17, 2025
• First Posted: January 2, 2026
• Study Start: February 7, 2025
• Primary Completion: February 1, 2026
• Study Completion: February 1, 2026
• Last Updated: January 2, 2026

Record last verified: 2025-12

Locations

FR (1)